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Abstract
Background: Early diagnosis is of substantial benefit for patients with Pompe disease.
Yet underdiagnosing and substantial diagnostic delay are still frequent and the determi-
nants of this are unknown. This study is the first to systematically investigate the diag-
nostic odyssey in Pompe disease from patients', parents', and physicians' perspectives.
Methods: Patients with infantile or late onset Pompe disease, their parents as well as
their metabolic experts were invited to fill in respective surveys. The survey
addressed perceived disease symptoms at onset and during the course of the disease,
specialties of involved physicians, activities of patient-initiated search for diagnosis
and the perceived impact of time to diagnosis on outcome. Results of experts' and
patients'/parents' surveys were compared and expressed by descriptive statistics.
Results and Discussion: We collected data on 15 males and 17 females including
9 infantile and 23 late onset Pompe patients. All received the correct diagnosis at a met-
abolic or musculoskeletal expert center. Patients with direct referral to the expert center
had the lowest diagnostic delay, while patients who were seen by several physicians,
received the correct diagnosis after 44%-200% longer delay. The proportion of direct
referral varied strongly between pediatricians (57%) and other disciplines (18%-36%).
Conclusion: Our study highlights a substantially larger diagnostic delay in Pompe
patients that are not directly referred to expert centers for diagnostic work. Our
findings may be used to develop more successful strategies for early diagnosis.
Synopsis
Diagnostic delay in Pompe disease is substantial particularly in patients that are not
directly referred to expert centers for diagnostic workup, so facilitating direct refer-
ral may be a new strategy for early diagnosis.
Abbreviations: ERT, enzyme replacement therapy; GAA, acid alpha glucosidase; HCP, health care provider; IOPD, infantile onset Pompe disease; LOPD,
late onset Pompe disease; OMIM, online mendelian inheritance in man.
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1 | INTRODUCTION
Pompe disease (glycogen storage disease type II; OMIM
#232300) is a progressive, debilitating, and potentially fatal
myopathy. It is caused by an autosomal recessive inherited
deficiency of the lysosomal enzyme acid alpha glucosidase
(GAA) and is estimated to affect 1:40 000 individuals.1
GAA deficiency leads to intralysosomale and intracellular
accumulation of glycogen, alteration of autophagy and cell
signaling, and consecutively to progressive skeletal and car-
diac muscle cell dysfunction and death.2-5 The phenotypic
spectrum is broad and ranges from classic infantile Pompe
disease (IOPD) to attenuated, late onset forms (LOPD). In
IOPD, glycogen storage starts even before birth and most
affected children become symptomatic within the first weeks
of life. If untreated, IOPD progresses rapidly to fatal cardiac
and respiratory failure mostly within the first two years of
life.5 The incidences of IOPD and LOPD have been esti-
mated to 1 in 138 000 and 1 in 57 000 births, respec-
tively.1,6,7 LOPD may present any time from childhood to
old age with initially nonspecific symptoms. The course of
LOPD is highly variable. Delayed achievements of motor
milestones, recurrent severe respiratory infections, failure to
thrive/weight loss as well as impaired exercise tolerance,
fatigue, and signs of progressive myopathy and respiratory
insufficiency have been observed. Cardiomyopathy is not a
characteristic feature of LOPD.
At present, Pompe disease is treatable but not curable.
Enzyme replacement therapy (ERT) has a significant positive
effect on ventilator free survival time and heart muscle in IOPD
patients and may alter the clinical course favorably in LOPD.
Early diagnosis seems to be of significant value.8,9 Additionally,
setting the diagnosis of Pompe disease improves quality of care
by opening the gate to specialized multidisciplinary centers and
genetic counseling services.10-12 Unfortunately, poor recogni-
tion, underdiagnosing,13 and substantial diagnostic delay are
still frequent and a number of awareness raising campaigns
showed no obvious effects.11,12,14 Yet determinants of diagnos-
tic failure or delay have not yet been systematically studied.
This motivated us to explore patients', parents', and physicians'
perspectives on factors associated with diagnostic delay as a
first step toward improved strategies to reduce the diagnostic
delay in Pompe disease.
2 | METHODS
2.1 | Participants
Experts in pediatric and adult metabolic medicine following
patients with Pompe disease from six centers in Austria
(Bregenz, Salzburg), Germany (Mainz), and Switzerland
(Bern, St. Gallen, Zurich) agreed to participate and recruit pat-
ients/parents for the study. The participating sites included a
very large center as well as medium and small-size centers.
After the respective institutional review boards (Salzburg,
Vorarlberg, Zurich, Rhineland Palatinate) had given their
approval (415-EP/73/332-2014; EK-Nr. 2014-2/2; KEK-ZH-
Nr. 2014-0111, 837.277.14[9516]), all patients with proven
Pompe disease and their parents were invited to participate.
All participants gave informed consent and completed a spe-
cifically developed survey.
2.2 | Data collection
Specific surveys for patients, parents, and experts (as a case
report form for chart review) were made available for online data
entry via Survey Monkey (https://de.surveymonkey.com/). To
minimize selection bias, a printed copy of the survey was pro-
vided to patients/parents who preferred this to the online tool.
2.3 | Data analysis
Printed copy data were entered into the database by the
study team. Data were analyzed using the SPSS version
21 software. Categorical data were expressed as proportion
of total number of patients in the respective disease form
group. Continuous data were calculated as mean, median,
minimum, and maximum. Correlations were calculated after
rank-transformation using the Spearman-rank method. P-
values less than .05 were considered significant.
2.4 | Definitions
Patients with onset of symptoms during the first year of life
were classified as IOPD patients; the remaining patients
were classified as LOPD. Diagnostic delay was defined as
the time between onset of symptoms and setting of the diag-
nosis. The term “diagnostic odyssey” in Pompe disease
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indicates a patients' journey from the first contact with a
health care provider (HCP) to the expert center that are
defined as metabolic (infants or children) or neuromuscular
centers (adults).
3 | RESULTS
We collected data on 15 male and 17 female patients. Nine
patients were classified as IOPD, 23 as LOPD. Twenty-one
patients and 11 parents (2 fathers, 8 mothers, 1 missing infor-
mation) completed the respective surveys. Seven experts com-
mented on five IOPD and 22 LOPD cases.
3.1 | Involved HCP
Patients with IOPD had been seen by general pediatricians
(67%), physical therapists (22%), and neurologists (11%)
before referral to a metabolic or neuromuscular expert.
LOPD patients had consulted general practitioners (50%),
neurologists (40%), physical therapists (20%), orthopedists
(15%), and pediatricians (5%). Patients with IOPD consulted
1-2 (median 1) different HCP before referral to the metabolic
center as compared to 1-6 (median 2) HCP in LOPD.
3.2 | Diagnostic delay
In IOPD patients, parents retrospectively dated disease onset
in their child to the age of 7 months in median (range
0-12 months). The correct diagnosis was set with a delay of
2.5 (1.5-6) months.
Twenty-two percent of patients/parents with a diagnos-
tic delay between 6-12 months (median 6 months) consid-
ered this diagnostic delay inacceptable and associated with
negative consequences on disease outcome. Sixty-seven
percent of IOPD patients/parents judged the delay as
acceptable or satisfying.
LOPD patients were diagnosed 144 (12-480) months after
the onset of first symptoms at a median age of 26 (3-60)
years. The delay was acceptable for 22% and satisfying for
39% of patients/parents. One (4%) participant considered the
delay inacceptable but provided no information on its extent.
Forty-three percent of LOPD patients/parents stated that the
diagnostic delay had no negative consequences on outcome
while 17% felt the long diagnostic delay was “crucial” for
their current physical status. Figure 1 illustrates that age at
onset and diagnostic delay are positively correlated (R = .82).
Twelve of the complete sample of 32 patients had been
referred directly to an expert center after initial assessment
by a pediatrician (4), general practitioner (4), neurologist
(2), orthopedist (1), or internist (1).
Twenty of 32 patients had been seen by 2 to 6 different
HCP before referral to the expert and diagnosis. Overall
diagnostic delay was less in IOPD and LOPD patients referred
directly to the expert center (1.5-264, median 112 months) as
compared to other referral strategies (1.5-480, median
178 months). Serial referral to nonexpert HCP increases the
median diagnostic delay in IOPD and LOPD patients primarily
seen by pediatricians from 4 to 12 (+200%) months and in all
other patients from 132 to 190 (+44%) months in median.
Figure 2 illustrates the delay to diagnosis in relation to the diag-
nostic odyssey and highlights substantial differences between
patients initially seen by pediatricians and those seen by
other HCP.
3.3 | Symptoms at onset and during the
disease course
Expert chart review revealed generalized muscular hypotonia,
weak sucking and crying, hypomimic face and macroglossia as
leading initial symptoms in 80% of IOPD patients (Figure 3A).
During the course of the disease additionally motor retardation,
activity-induced tachypnoea/dyspnoea, excessive sweating as
well as respiratory infections were noticed in 80% of IOPD
patients.
In LOPD, experts perceived muscle weakness of hips/legs
and trunk (86 and 77%, respectively), reduced performance in
sports (73%), and difficulties to cope with every day-life
(68%) (Figure 3B) as most common first symptoms of LOPD.
During the course of the disease, main limitations and symp-
toms were diminished resilience in school/job (86%), back
pain (64%) sleeping disturbances and nonrestorative sleep
(59% and 55%), fatigue (59%), weakness of the arms (59%),
and exercise-induced tachy−/dyspnoea (63.6%).
Interestingly, symptom patterns differed only slightly
between patients' and experts' reports (Figure 3C,D). In IOPD,
experts reported weak crying and signs of dysphagia much
more frequently than parents did. In LOPD, patients/parents
FIGURE 1 Rank correlation (Spearman) of diagnostic delay and
age of onset
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reported drooling more frequently than experts did. Otherwise,
leading symptoms were quite congruent.
As expected, the prevalence of symptoms increased dur-
ing the course of disease underlining the progressive charac-
ter of the disease.
3.4 | Inaccurate diagnoses
Eleven of 32 (34%) of the patients reported on incorrect diagno-
ses they had received before seeing the metabolic or neuromus-
cular expert. In LOPD “unclear muscle dystrophy/hypotonia/
weakness” was reported most frequently (5/11) followed by
“ankylosing spondylitis/degenerative back disease” (2/11).
“Depression”, “fatigue,” and “gait abnormalities” were consid-
ered in individual patients. In IOPD the diagnoses “unclear
weight loss,” “mononucleosis,” “birth injury,” and “hip dyspla-
sia”were reported.
3.5 | Self-initiated search for diagnosis
Three parents of IOPD patients and six LOPD patients (36%)
had performed a self-initiated internet search. The predomi-
nantly used search-engine was Google, followed by Yahoo.
A single patient referred to Pubmed as primary source for
information. One LOPD patient consulted medical literature,
and one patient contacted medical institutions for help.
4 | DISCUSSION
This study is the first approach to systematically investigate
the diagnostic odyssey in IOPD and LOPD, its association
with diagnostic delay and perceived impact on outcome
from a patients' / parents' as well as the expert perspective.
Our results indicate that a diagnostic odyssey with involve-
ment of several HCPs is associated with a substantial
increase of diagnostic delay (+ 44%-200%). This encourages
the development of novel strategies to improve the timely
diagnosis of Pompe disease and other rare diseases.
Our data are in good accordance with previous, partly
very large studies [14] with regard to the following findings:
IOPD with cardiomyopathy was the smallest patient fraction
(11%) in our sample with the earliest onset (1.5-3, median
3 months), a rather uniform clinical pattern and a rapidly
progressive course. Diagnostic delay (1.5-3, median
2.5 months) was shortest in this group, probably owing to
the course characteristics and the resulting diagnostic and
therapeutic impact.
FIGURE 2 Diagnostic delay by HCP involved. The figure shows which specialists (lower part) have been consulted for the initial signs and
symptoms of Pompe disease, the number of patients directly referred to an expert center (straight arrows in dark colors), and the number of patients
who underwent a diagnostic odyssey (winded arrows in light colors). In the top part the median diagnostic delay in months is compared between the
latter two groups indicating approximately a duplication of delay by the diagnostic odyssey
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In contrast, LOPD represented 67% and probably due to the
heterogeneous presentation and course—showed a substantial
diagnostic delay (12-480, median 144 months). Additionally,
symptoms at presentation and throughout the disease course as
collected by expert chart review and the rate of misdiagnosing
(34%) were congruent with published data (http://www.
eurordis.org/IMG/pdf/voice_12000_patients/EURORDISCARE_
FULLBOOKr.pdf) indicating sufficient representativeness of
our sample.
Patients' views have rarely been studied9,15-17 and thus
our results may offer options for new awareness raising strat-
egies for Pompe disease.
Our hypothesis that patients'/parents' views and description
of first symptoms might differ substantially from textbook
knowledge on Pompe disease and may thus be misleading for
physicians in the first place was not supported by our data.
The description of initial symptoms differed only slightly
between patients/parents and physicians and no novel red flag
symptoms/terms of description could be identified.
Self-initiated search for diagnosis was surprisingly infre-
quent in our study. However, most participating patients had
been diagnosed before the internet became easily accessible
and widely used. Like in other rare conditions18,19 provision
of information via the internet and social media may be help-
ful in directing Pompe disease patients to the expert.
Beyond pediatricians and neurologists, Pompe disease
patients in our study first encountered also physical thera-
pists, general practitioners, and orthopedists. These profes-
sions have so far not been and could in the future be taken
into account as target groups for awareness-raising cam-
paigns in Pompe disease.20
All patients finally received their correct diagnosis in a
center with expertise in metabolic or neuromuscular dis-
eases. The proportion of patients directly referred to an
expert center varied substantially, dependent on the HCP
seen first (18% direct referral by neurologists to 57% by
pediatricians) (Figure 2). This effect is of course confounded
with age, disease presentation, and progression.
FIGURE 3 Symptoms as specified by parents/patients vs experts
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Yet generally, direct referral is associated with a substan-
tially shorter delay even if the referral diagnosis is wrong or
unclear. Thus it seems worth considering a strategic shift by
complementing awareness-raising campaigns for involved
medical disciplines (with only limited success in the past14)
with actions facilitating early referral to expert centers.
As rare diseases generally share the challenge of diagnos-
tic delay, the now increasingly established centers for rare
diseases, which offer interdisciplinary expertise for many
rare diseases under one umbrella, could become key players
in this approach.
Our exploratory study is limited by its small sample size
and the retrospective survey methodology. Yet, the partici-
pation of small, medium size, and large centers from three
countries, the use of information retrieved independently
from patients/parents and experts and the overall consistency
of key data with larger studies indicate sufficient internal
and external validity.
5 | CONCLUSION
To our knowledge, this is the first systematic investigation on
the diagnostic odyssey in IOPD and LOPD, which assesses
the patients' as well as the expert's perspective. In conclusion,
our study not only corroborates the substantial diagnostic
delay in Pompe disease from previous publications,14-17 but it
gives clues toward an improved strategy to facilitate early
diagnosis of Pompe disease, which aims for early referral of
patients with unspecific symptoms to expert centers.
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